Next Article in Journal
Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer
Next Article in Special Issue
Phenotypic and Histological Distribution Analysis Identify Mast Cell Heterogeneity in Non-Small Cell Lung Cancer
Previous Article in Journal
Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups
Previous Article in Special Issue
Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung
 
 
Review
Peer-Review Record

Coordinated Regulation of Myeloid-Derived Suppressor Cells by Cytokines and Chemokines

Cancers 2022, 14(5), 1236; https://doi.org/10.3390/cancers14051236
by Ru Li, Mousumi Beto Mukherjee and Jun Lin *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2022, 14(5), 1236; https://doi.org/10.3390/cancers14051236
Submission received: 31 January 2022 / Revised: 23 February 2022 / Accepted: 25 February 2022 / Published: 27 February 2022
(This article belongs to the Special Issue Tumor-Associated Myeloid Cells)

Round 1

Reviewer 1 Report

Myeloid‐derived suppressor cells (MDSCs) are immature myeloid cells that impair immune cell functions and promote tumor progression. More and more evidence indicates that cytokines and chemokines in the tumor microenvironment regulate MDSCs. In this review, the authors summarize the current evidence on the regulation of myeloid‐derived suppressor cells by cytokines and chemokines. The review is well written. It is clear and succinct. Some minor revisions are suggested before publication:

  1. The authors discussed the cytokines/chemokines regulating neutrophils and monocytes in cancer. They can emphasize a little more about the reason behind choosing neutrophils and monocytes over other immune cells.
  2. The authors summarized some literature about cytokines/chemokines regulating monocytes, which should be extended into more detail.
  3. Some grammar errors.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The review paper by Ru Li and colleagues, is a well-written, comprehensive and updated overview of one of the most recent research breakthroughs in the field of cancer immunotherapy. I read the manuscript with interest. I have a few concerns though:

1. The part of characteristic features of MDSCs could further improve. I suggest giving more emphasis on markers used to identify MDSC populations.

2. The results of recent studies using the MDSC and their signalling pathway could be present in a more detailed way and maybe it would be a good idea to add a summary table.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

Authors responded to all my suggestions. I have no further comments.

Back to TopTop